Eton Pharmaceuticals (NASDAQ:ETON) Given New $17.00 Price Target at HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON) had its target price upped by HC Wainwright from $15.00 to $17.00 in a research note released on Monday morning, MarketBeat Ratings reports. HC Wainwright currently has a buy rating on the stock.

Separately, Craig Hallum lifted their price objective on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, October 28th.

Eton Pharmaceuticals Trading Down 6.5 %

NASDAQ ETON opened at $12.16 on Monday. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $15.00. The stock has a 50 day moving average of $11.44 and a 200-day moving average of $7.22. The company has a market cap of $316.78 million, a PE ratio of -55.27 and a beta of 1.38.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Parkman Healthcare Partners LLC lifted its holdings in Eton Pharmaceuticals by 2.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock valued at $1,561,000 after purchasing an additional 7,029 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eton Pharmaceuticals in the third quarter valued at about $54,000. Jane Street Group LLC acquired a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth about $90,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Eton Pharmaceuticals by 86.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after buying an additional 30,167 shares during the period. Finally, Geode Capital Management LLC grew its stake in Eton Pharmaceuticals by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock valued at $1,637,000 after buying an additional 32,365 shares during the last quarter. 27.86% of the stock is currently owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.